Pantoprazole Viatris (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Sodium Sesquihydrate, the active ingredient in Pantoprazole Viatris, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults.

GNH USA supplies Pantoprazole Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole Viatris is a proton‑pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and promotes healing of the oesophageal lining. - Erosive oesophagitis: heals erosions caused by chronic acid exposure. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production. - Maintenance therapy after healed erosive oesophagitis: helps prevent relapse.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: typically self‑limiting. - Nausea or vomiting: occasional and transient. - Abdominal pain or discomfort: usually mild. - Flatulence: occasional. - Constipation: infrequent.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe diarrhoea requiring medical attention. - Acute interstitial nephritis: sudden kidney inflammation. - Severe hypersensitivity reactions: rash, angio‑edema or anaphylaxis. - Osteoporotic fractures: increased risk with long‑term use. - Low magnesium (hypomagnesemia): may cause muscle cramps or cardiac arrhythmia. - Liver enzyme elevations: transient increases in ALT/AST.

When prescribing Pantoprazole, clinicians should consider several safety aspects: - Renal impairment: dose adjustment may be needed in severe kidney disease. - Hepatic impairment: use with caution in patients with moderate to severe liver dysfunction. - Long‑term therapy: monitor for bone density loss and magnesium levels. - Drug interactions: review concomitant medications for potential CYP‑related effects. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Antifungal azoles (ketoconazole, itraconazole): reduced absorption due to higher gastric pH. - HIV protease inhibitors (lopinavir/ritonavir): decreased plasma concentrations. - Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Methotrexate: reduced renal clearance may raise systemic exposure. - Digoxin: slight increase in serum levels. - Oral contraceptives: modest reduction in efficacy, advise backup contraception.